Alan P. Venook, M.D., FAnnual Meeting of Helen Diller Family Comprehensive Cancer Center discusses how to integrate immunotherapy into existing treatment regimens for CRC patients at the 2017 Gastrointestinal Cancers Symposium (Annual Meeting GI) in San Francisco, CA.
Author: Editor
Thomas A. Abrams, MD of Dana Farber Cancer Institute discusses how checkpoint inhibitors will be used in unresectable HCC treatment at the 2017 Gastrointestinal Cancers Symposium (Annual Meeting GI) in San Francisco, CA.
Thomas A. Abrams, MD of Dana Farber Cancer Institute discusses how targeted therapies seem to work better for patients with HCC at the 2017 Gastrointestinal Cancers Symposium (Annual Meeting GI) in San Francisco, CA.
Thomas A. Abrams, MD of Dana Farber Cancer Institute discusses regorafenib in clinical practice at the 2017 Gastrointestinal Cancers Symposium (Annual Meeting GI) in San Francisco, CA.
Thomas A. Abrams, MD of Dana Farber Cancer Institute gives an overview of the results of the RESORCE trial, that was presented at the 2017 Gastrointestinal Cancers Symposium (Annual Meeting GI) in San Francisco, CA.
Thomas A. Abrams, MD of Dana Farber Cancer Institute discusses new agents for the treatment of advanced HCC at the 2017 Gastrointestinal Cancers Symposium (Annual Meeting GI) in San Francisco, CA.
Arturo Loaisa-Bonilla, MD of the Abramson Cancer Center of the University of Pennsylvania discusses Gallium 68 versus Low Volume PRRT at ASCO GI 2017
Arturo Loaisa-Bonilla, MD of the Abramson Cancer Center of the University of Pennsylvania states that Gallium 68 should be Used Instead of Ultra Scan at ASCO GI 2017.
Arturo Loaisa-Bonilla, MD of the Abramson Cancer Center of the University of Pennsylvania discusses how Gallium 68 Provides Much More Data to Refine Treatment Options for clinicians at ASCO GI 2017.
Arturo Loaisa-Bonilla, MD of the Abramson Cancer Center answers the question Where to Put PRRT in the Treatment Paradigm at ASCO GI 2017.
Arturo Loaisa-Bonilla, MD of Abramson Cancer Center discusses the relationship between Theranostics and Sumaratin Receptors in Neuroendocrine Cells at ASCO GI 2017
As part of our ASH 2016 coverage, Dr. John Mascarenhas, from Mount Sinai School of Medicine, joined Patient Power to discuss the research taking place with interferon as a treatment for myeloproliferative neoplasms (MPNs). While interferon has been around for some time, theres a recent re-emergence of research in the field. Dr. Mascarenhas addresses the interim results of current studies and the new clinical trials set to begin in 2017. Learn more about interferon and why this may be a viable option for some patients with MPNs. Get email alerts | http://www.patientpower.info/alerts Subscribe on YouTube | http://www.youtube.com/patientpower Like on Facebook…
Ian Chau, MD, FRCP of Royal Marsden Hospital discusses how Nivolumab Shows Significant Overall Survival Benefit in Metastatic Gastric Cancer at ASCO GI 2017
Ian Chau, MD, FRCP of Royal Marsden Hospital discusses the Potential Scenarios for Ramucirumab plus Pembrolizumab at ASCO GI 2017
Arturo Loaisa-Bonilla, MD of Abramson Cancer Center discusses how Gallium 68 Scan has now Become Standard for Staging Neuroendocrine Tumors from ASCO GI 2017
Davendra Sohal, MD of Cleveland Clinic outlines the Pancreatic Cancer Trends for 2017 from ASCO GI 2017
Davendra Sohal, MD of Cleveland Clinic discusses that Improvement in Systemic Therapies are Needed in in Pancreatic Cancer from ASCO GI 2017
In this Best of the Day discussion from the annual hematology meeting held in San Diego, Drs. Joseph R. Mikhael and Sonali M. Smith analyze and discuss pertinent clinical studies and late breaking updates pertaining the care of patients with lymphoma. This engaging conversation provides updates in a comprehensive and accessible format that facilitates the incorporation of the latest treatment advances into clinical practice. Earn CME credit for this activity at the following location: https://elc.imedex.com/ELC/Activity-Overview.aspx?activityid=7243&specialty=Hematology
In this Best of the Day discussion from the annual hematology meeting held in San Diego, Drs. Joseph R. Mikhael and David P. Steensma analyze and discuss pertinent clinical studies and late breaking updates pertaining the care of patients with acute myeloid leukemia (AML) and myelodysplastic syndromes (MDS). This engaging conversation provides updates in a comprehensive and accessible format that facilitates the incorporation of the latest treatment advances into clinical practice. Earn CME credit for this activity at the following location: https://elc.imedex.com/ELC/Activity-Overview.aspx?activityid=7242&specialty=Hematology
In this Best of the Day discussion from the annual hematology meeting held in San Diego, Drs. Joseph R. Mikhael and Saad V. Usmani analyze and discuss pertinent clinical studies and late breaking updates pertaining the care of patients with multiple myeloma. This engaging conversation provides updates in a comprehensive and accessible format that facilitates the incorporation of the latest treatment advances into clinical practice. Earn CME credit for this activity at the following location: https://elc.imedex.com/ELC/Activity-Overview.aspx?activityid=7241&specialty=Hematology
In this Best of the Day discussion from the annual hematology meeting held in San Diego, Drs. Joseph R. Mikhael and Neil E. Kay analyze and discuss pertinent clinical studies and late breaking updates pertaining the care of patients with chronic lymphocytic leukemia (CLL). This engaging conversation provides updates in a comprehensive and accessible format that facilitates the incorporation of the latest treatment advances into clinical practice. Earn CME credit for this activity at the following location: https://elc.imedex.com/ELC/Activity-Overview.aspx?activityid=7240&specialty=Hematology
In this Best of the Day discussion from the annual hematology meeting held in San Diego, Drs. Joseph R. Mikhael and Ruben A. Mesa analyze and discuss pertinent clinical studies and late breaking updates pertaining the care of patients with chronic myelogenous leukemia (CML) and myeloproliferative neoplasms (MPN). This engaging conversation provides updates in a comprehensive and accessible format that facilitates the incorporation of the latest treatment advances into clinical practice. Earn CME credit for this activity here: https://elc.imedex.com/ELC/Activity-Overview.aspx?activityid=7239&specialty=Hematology
Davendra Sohal, MD of Cleveland Clinic presents the Results from Internal Expedience Borderline Resectable Pancreas Cancer at ASCO GI 2017
David Ilson, MD of Memorial Sloan Kettering outlines Potential Practicing Changing Data from ASCO GI 2017
David Ilson, MD of Memorial Sloan Kettering gives an in depth overview of the data presented at ASCO GI 2017
Howard S. Hochster, MD of Yale Cancer Center discusses how healthcare professionals will be integrating immunotherapy into existing treatment regimens for GI cancer patients at the 2017 Gastrointestinal Cancers Symposium (Annual Meeting GI) in San Francisco, CA.
Howard S. Hochster, MD of Yale Cancer Center discusses the outcomes of the randomized phase 2 study in BRAF-mutated patients with colorectal cancer at the 2017 Gastrointestinal Cancers Symposium (Annual Meeting GI) in San Francisco, CA.
David Ilson, MD of Memorial Sloan Kettering describes the Advantages of Induction Chemotherapy in Esophageal Cancer at ASCO GI 2017
Howard S. Hochster, MD of Yale Cancer Center discusses how genetic profiling has changed the treatment approach for patients with colorectal cancer at the 2017 Gastrointestinal Cancers Symposium (Annual Meeting GI) in San Francisco, CA.
Cynthia Sears, MD of Johns Hopkins sees a promising link to Microbiome Study and MSI Colorectal Cancer Immunotherapy. Interviewed at ASCO GI 2017
Howard S. Hochster, MD of Yale Cancer Center discusses how to use both TAS-102 and Regorafenib in patients with metastatic colorectal cancer at the 2017 Gastrointestinal Cancers Symposium (Annual Meeting GI) in San Francisco, CA.
Davendra Sohal, MD of Cleveland Clinic answers the question Will SWOG S1505 Impact Treatment of Pancreatic Cancer at ASCO GI 2017
Howard S. Hochster, MD of Yale Cancer Center discusses the difference between Regorafenib, 5FU, and TAS-102 at the 2017 Gastrointestinal Cancers Symposium (Annual Meeting GI) in San Francisco, CA.
Ghassan Abou-Alfa, MD, MBA of Memorial Sloan Kettering gives his view on checkpoint inhibitors and their incorporation into treatment for unresectable HCC at the 2017 Gastrointestinal Cancers Symposium (Annual Meeting GI) in San Francisco, CA.
Ghassan Abou-Alfa, MD, MBA of Memorial Sloan Kettering Cancer Center discusses his view on reliably identifying subgroups of patients for targeted therapies in HCC at the 2017 Gastrointestinal Cancers Symposium (Annual Meeting GI) in San Francisco, CA.
Ghassan Abou-Alfa, MD, MBA of Memorial Sloan Kettering Cancer Center discusses his thoughts on whether or not physicians will start incorporating regorafenib into clinical practice at the 2017 Gastrointestinal Cancers Symposium (Annual Meeting GI) in San Francisco, CA.
Ghassan Abou-Alfa, MD, MBA of Memorial Sloan Kettering Cancer Center gives his take on the outcomes of the RESORCE trial, which was presented at the 2017 Gastrointestinal Cancers Symposium (Annual Meeting GI) in San Francisco, CA.
Ghassan Abou-Alfa, MD, MBA of Memorial Sloan Kettering Cancer Center gives his take on integration of new agents for advanced HCC treatment at the 2017 Gastrointestinal Cancers Symposium (Annual Meeting GI) in San Francisco, CA.
SCCA’s Dr. Ajay Gopal discusses treatment options in lymphoma and chronic lymphocitic leukemia (CLL), as well as the strength of Seattle Cancer Care Alliance’s network that brings better results and stronger information to more patients and providers throughout the pacific northwest and Hawaii.
Nevena Damjanov, MD of University of Pennsylvania talks about how checkpoint inhibitors will be incorporated into unresectable HCC treatment at the 2017 Gastrointestinal Cancers Symposium (Annual Meeting GI) in San Francisco, CA.
Nevena Damjanov, MD of University of Pennsylvania discusses how healthcare professionals can reliably identify subgroups of patients for targeted therapies in HCC at the 2017 Gastrointestinal Cancers Symposium (Annual Meeting GI) in San Francisco, CA.
Nevena Damjanov, MD of University of Pennsylvania discusses how regorafenib will be incorporated into clinical practice at 2017 Gastrointestinal Cancers Symposium (Annual Meeting GI) in San Francisco, CA.
Nevena Damjanov, MD of University of Pennsylvania gives an overview of the outcomes of the RESORCE Trial that were presented at the 2017 Gastrointestinal Cancers Symposium (Annual Meeting GI) in San Francisco, CA.
Nevena Damjanov, MD of University of Pennsylvania discusses how new agents being studied for advanced HCC will be integrated into treatment at the 2017 Gastrointestinal Cancers Symposium (Annual Meeting GI) in San Francisco, CA.
David Ilson, MD of Memoral Sloan Kettering Cancer Center discusses data released at ASCO GI 2017. A total of 198 patients who completed chemoradiation were analyzed for the primary endpoint of pCR. Among the entire group, the pCR rate was 22.7%. The highest pCR rate of 37.5% occurred in PET responders who received both induction and concurrent FOLFOX, whereas the lowest rate of 12.5% occurred in PET responders who received both induction and concurrent carboplatin/paclitaxel. Notably, the pCR rate for PET nonresponders who switched from FOLFOX to carboplatin/paclitaxel was 19.0% and for those who switched from carboplatin/paclitaxel to FOLFOX was…
Cynthia Sears, MD of John Hopkins University School of Medicine highlights there is Accumulating evidence that the microbiome may play a role in colorectal cancer from ASCO GI 2017.
A cancer research team led by Dean Tang, PhD, found a specific miRNA (or microRNA) molecule that stunts prostate cancer spread. Dr. Tang, Roswell Park’s Chair of Pharmacology and Therapeutics, explains how miR-141 may play a role in the inhibition of prostate cancer metastasis.
Michael Soulen, MD of Hospital of the University of Pennsylvania gives an update on the RETNET Trial or the Randomized Embolization Trial for NeuroEndocrine Tumor Metastases To The Liver from ASCO GI 2017
Davendra Sohal, MD of Cleveland Clinic outlines the SWOG S1505 Clinical Trial Requirements at ASCO GI 2017
Johanna Bendell, MD of Sarah Cannon Research Institute discusses the Proprietary Neoantigen Identification Technology Platform at the 2017 Gastrointestinal Cancers Symposium (Annual Meeting GI) in San Francisco, CA.